Nurse Practitioner Program year 2025 Reported 2023–2025 Source: CMS Open Payments, 2026 publication

Morgan Hoffman

Nurse Practitioner Baton Rouge, LA Nurse Practitioner

NPI 1467044669 CMS profile 11233055

10310 The Grove Blvd, Baton Rouge, LA 70836

Open in the dashboard

General payments

$11,559

497 records reported · program years 2023–2025

Research payments

$0

Paid to them · None reported · program years 2023–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Morgan Hoffman of Baton Rouge, LA is reported in the CMS Open Payments database as having received $11,559 across 497 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Nurse Practitioner profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

3 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,538 145
2024 General $4,807 211
2023 General $3,215 141

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Morgan Hoffman
  • Nurse Practitioner median
  • Middle half of Nurse Practitioner
  • National median

In program year 2025, general payments to Morgan Hoffman were reported at $3,538. Among 41,044 Nurse Practitioner profiles paid that year, the median was $174 and the middle half received between $55 and $557.

Show as a table
Year Morgan Hoffman Nurse Practitioner median Middle half National median
2019 $0 $50 $22–$97 $163
2020 $0 $40 $16–$108 $114
2021 $0 $135 $40–$426 $132
2022 $0 $152 $48–$470 $149
2023 $3,215 $166 $54–$529 $160
2024 $4,807 $173 $55–$556 $164
2025 $3,538 $174 $55–$557 $169

Breakdown

Who paid General payments · program years 2023–2025
  1. AbbVie, Inc. $3,325 143 payments
  2. Amgen Inc. $1,124 59 payments
  3. UCB, Inc. $956 48 payments
  4. Pfizer Inc. $910 53 payments
  5. GlaxoSmithKline, LLC. $894 31 payments
  6. Janssen Biotech, Inc. $674 27 payments
  7. AstraZeneca Pharmaceuticals LP $573 19 payments
  8. Novartis Pharmaceuticals Corporation $523 22 payments
  9. Mallinckrodt Hospital Products Inc. $518 21 payments
  10. Genzyme Corporation $322 10 payments
  11. Other $1,742 64 payments

Every payment, record by record

What the payments were for General payments · program years 2023–2025
  1. Food and Beverage $11,375 495 payments
  2. Education $184 2 payments
Products named General payments · program years 2023–2025
  1. RINVOQ $2,070 83 payments
  2. TREMFYA $933 30 payments
  3. SKYRIZI $786 33 payments
  4. Cimzia $587 31 payments
  5. SAPHNELO $573 19 payments
  6. BENLYSTA $570 28 payments
  7. ACTHAR $518 21 payments
  8. PANZYGA $467 19 payments
  9. OCTAGAM IMMUNE GLOBULIN (HUMAN) $467 19 payments
  10. COSENTYX $442 19 payments
  11. Other $4,966 266 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 23 billing codes

Paid by Medicare

$86,562

Of which drugs: $57,526

Medicare patients

286

Average age 70

Services billed

10,012

235 women, 51 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Depression 31%
Osteoporosis 29%
Chronic kidney disease 28%
Diabetes 25%
Ischemic heart disease 23%
COPD 19%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, denosumab, 1 mg J0897 Office 23 1,380 $28,389
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 56 307 $231
Injection, methylprednisolone acetate, 1 mg J1010 Office 18 1,400 $138
Injection, ketorolac tromethamine, per 15 mg J1885 Office 12 52 $25

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 37 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
RINVOQ
$842 — —
SKYRIZI
$504 — —
TREMFYA
$446 — —
SAPHNELO
$273 — —
Cimzia
$270 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 37 with Patron

Records

497 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner in Louisiana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record